CTOs on the Move

Abeo Management Corporation

www.abeo.com

 
abeo is a nationwide medical billing and software company focused on delivering revenue-enhancing services to private practices, hospitals and surgery centers. We bridge the gap between the constant change in healthcare and your changing needs as a result. We know the healthcare landscape; we know the complexities and regulations. Our professional management services, medical billing software and anesthesia advisory services are tailored to improve the operational and financial performance for the specialty of anesthesiology. We blend our employee expertise in anesthesia with process and technology to take efficiency to the next level. Operational best practices play a key role in our ...
  • Number of Employees: 1K-5K
  • Annual Revenue: > $1 Billion
  • www.abeo.com
  • 5001 LBJ Freeway Suite 320
    Dallas, TX USA 75244
  • Phone: 972.861.1270

Executives

Name Title Contact Details
Joe Ferro
Chief Technology and Innovation Officer Profile

Similar Companies

Antech Diagnostics

Antech sets the standard for reference laboratory and imaging excellence. At the heart of our company is our love for pets, their health, and their…

Lets Talk Spech Language Svcs

Lets Talk Spech Language Svcs is a Raleigh, NC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

MD Home Health and Staffing

MD Home Health and Staffing is a Phoenix, AZ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Dale Commons Assisted Living

Dale Commons Assisted Living is a Modesto, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Geron

We are a biopharmaceutical company developing first-in-class therapies for cancer. Imetelstat, a novel, first-in-class telomerase inhibitor, is our product candidate in clinical development. Telomerase enables cancer cells to maintain telomere length, which provides them with the capacity for limitless cellular replication. Imetelstat is a potent and specific inhibitor of telomerase. Based on clinical data we obtained in late 2012, we may develop imetelstat to treat one or more hematologic myeloid malignancies such as myelofibrosis, or MF, myelodysplastic syndromes, or acute myelogenous leukemia.